BioTuesdays

Category - News

Savara Logo

HCW starts Savara at buy; PT $22

H.C. Wainwright initiated coverage of Savara (NASDAQ:SVRA) with a “buy” rating and $22 price target. The stock closed at $8.88 on May 25. Savara is developing two compounds, Molgradex, and AeroVanc that we believe, are...

Scynexis Logo

Ladenburg starts Scynexis at buy; PT $9

Ladenburg Thalmann launched coverage of Scynexis (NASDAQ:SCYX) with a “buy” rating and price target of $9. The stock finished at $1.59 on May 23. Scynexis is focused on developing a first-in-class antifungal, SCY-078...

Avid Bioservices

HCW starts Avid Bioservices at buy; PT $5

H.C. Wainwright launched coverage of Avid Bioservices (NASDAQ:CDMO) with a “buy” rating and $5 price target. The stock closed at $3.56 on May 23. Avid has accumulated 25 years of biologics cGMP experience, including...

Canaccord Logo

Canaccord cuts Vermillion to hold; PT to $1

Canaccord Genuity downgraded Vermillion (NASDAQ:VRML) to “hold” from “buy” and lowered its price target to $1 from $2.25 after the company’s first quarter results missed estimates across the board. The stock closed at...

Ortho Regenerative Technologies

Ortho RTi receives European patent allowance

Ortho Regenerative Technologies (CSE:ORTH) received a notice of allowance from the European Patent Office for a patent entitled, “Soluble Physiological Chitosan Formulations Combined with Platelet-Rich Plasma...

Cesca Therapeutics Logo

HCW starts Cesca Therapeutics at buy; PT $1.50

H.C. Wainwright launched coverage of Cesca Therapeutics (NASDAQ:KOOL) with a “buy” rating and $1.50 price target. The stock closed at 53 cents on May 22. Cesca is focused on cell-based therapies and automated cell...

Citius Logo

HCW starts Citius Pharma at buy; PT $11

H.C. Wainwright initiated coverage of Citius Pharmaceuticals (NASDAQ:CTXR) with a “buy” rating and price target of $11. The stock finished at $2.40 on May 22. The company’s antibiotic lock therapy drug combination, Mino...